**Name of Journal: *World Journal of Critical Care Medicine***

**ESPS Manuscript NO: 20573**

**Manuscript Type: MINIREVEWS**

**Preemptive mechanical ventilation can block progressive acute lung injury**

Sadowitz B *et al.* Preemptive mechanical ventilation can block progressive ALI

**Benjamin Sadowitz, Sumeet Jain, Michaela Kollisch-Singule, Joshua Satalin, Penny Andrews, Nader Habashi, Louis A Gatto, Gary Nieman**

**Benjamin Sadowitz,** the Southeastern Center for Digestive Disorders and Pancreatic Cancer,Advanced Minimally Invasive and Robotic Surgery,Florida Hospital Tampa,Tampa, FL 33613, United States

**Sumeet Jain, Michaela Kollisch-Singule, Joshua Satalin, Gary Nieman,** Department of Surgery, Upstate Medical University, Syracuse, NY 13210, United States

**Penny Andrews, Nader Habashi,** Critical Care Medicine,Surgical Critical Care, Trauma Critical Care Medicine, The R Adams Cowley Shock Trauma Center, University of Maryland, Baltimore, MD 21201, United States

**Louis A Gatto,** Biological Sciences Department, SUNY Cortland,Cortland, NY 13045, United States

**Author contributions:** Sadowitz B contributed to acquisition of data, data interpretation and analysis, drafting the manuscript; Jain S, Kollisch-Singule M, Satalin J, Andrews P, Habashi N, Gatto LA and Nieman G contributed to data interpretation and analysis, critical revision of the manuscript.

**Conflict-of-interest** **statement:** We have no conflict of interests to disclose.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to: Joshua Satalin, Lab Manager** (Cardiopulmonary Critical Care Lab),Department of Surgery, Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, United States. satalinj@upstate.edu

**Telephone:**  +1-315-4641696

**Received:** June 10, 2015

**Peer-review started:** June 11, 2015

**First decision:** August 25, 2015

**Revised:** October 15, 2015

**Accepted:** December 29, 2015

**Article in press:**

**Published online:**

**Abstract**

Mortality from acute respiratory distress syndrome (ARDS) remains unacceptable, approaching 45% in certain high-risk patient populations. Treating fulminant ARDS is currently relegated to supportive care measures only. Thus, the best treatment for ARDS may lie with preventing this syndrome from ever occurring. Clinical studies were examined to determine why ARDS has remained resistant to treatment over the past several decades. In addition, both basic science and clinical studies were examined to determine the impact that early, protective mechanical ventilation may have on preventing the development of ARDS in at-risk patients. Fulminant ARDS is highly resistant to both pharmacologic treatment and methods of mechanical ventilation. However, ARDS is a progressive disease with an early treatment window that can be exploited. In particular, protective mechanical ventilation initiated before the onset of lung injury can prevent the progression to ARDS. Airway pressure release ventilation (APRV) is a novel mechanical ventilation strategy for delivering a protective breath that has been shown to block progressive acute lung injury (ALI) and prevent ALI from progressing to ARDS. ARDS mortality currently remains as high as 45% in some studies. As ARDS is a progressive disease, the key to treatment lies with preventing the disease from ever occurring while it remains subclinical. Early protective mechanical ventilation with APRV appears to offer substantial benefit in this regard and may be the prophylactic treatment of choice for preventing ARDS.

**Key words:** Mechanical ventilation; Acute lung injury; Acute respiratory distress syndrome; Airway pressure release ventilation

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Mortality from acute respiratory distress syndrome (ARDS) remains unacceptably high. Treating fulminant ARDS, however, is currently relegated to supportive care measures only. Thus, the best treatment for ARDS may lie with preventive measures. Indeed, since ARDS is a progressive disease, treating this disease in its subclinical phases may prevent the disease from ever occurring. In this regard, early protective mechanical ventilation with airway pressure release ventilation appears to offer substantial benefit and may be the prophylactic treatment of choice for preventing ARDS.

Sadowitz B, Jain S, Kollisch-Singule M, Satalin J, Andrews P, Habashi N, Gatto LA, Nieman G. Preemptive mechanical ventilation can block progressive acute lung injury. *World J Crit Care Med* 2016; In press

**ACUTE RESPIRATORY DISTRESS SYNDROME AND ITS SEQUELAE REMAIN A MAJOR AND COSTLY PUBLIC HEALTH CARE BURDEN**

Acute respiratory distress syndrome (ARDS) and its sequelae remain a significant public health care burden in North America and worldwide[1-3]. The mean hospital costs for a patient with ARDS can easily cross the $100000 mark before discharge; this figure does not include the cost of subsequent hospital visits for complications from ARDS or any outpatient services including physical therapy, in-home nursing, or pharmaceuticals[1].

Compounding this significant cost is the broad spectrum of disability suffered by ARDS patients[2-6]. These disabilities are both physical and psychological, and they can last for at lease 5 years after the initial ARDS insult[1-6]. Most importantly, the sum total of these disabilities ultimately leads to a quality of life for ARDS patients that is significantly reduced compared to both the general population and other patients without ARDS who survived a critical illness[4,6].

It would appear that the most effective way to reduce the economic, physical, and psychological burden of ARDS would be *via* prevention of the disease process from ever occurring. Fulminant ARDS is resistant to all current treatment therapies, be they pharmacologic, mechanical, or a combination of the two[7-9]. We believe, however, that employment of a protective ventilation strategy early in the course of acute lung injury (ALI) or in patients at risk for ALI can block progression of this disease and prevent ARDS. Thus, our goal with this review is to detail the longstanding futility of treating established ARDS while examining the evidence that preemptive protective mechanical ventilation can reduce ARDS incidence. Furthermore, we will examine both the basic science and clinical studies demonstrating that airway pressure release ventilation (APRV) is the premier mode of ventilation for delivering an optimal protective breath with a specific Mechanical Breath Profile (MBP) that prevents progression to ARDS for those patients at risk.

**ONCE ESTABLISHED, THERE ARE NO EFFECTIVE TREATMENTS FOR ARDS**

The landmark ARDSnet trial in 2000 marked the first time in decades that a significant, positive treatment effect was noted in patients with ALI and ARDS. In this trial, patients with ALI or ARDS were randomized to a “traditional”, high-tidal volume (12 cc/kg) ventilation group or a low-tidal volume (6 cc/kg) ventilation group. The trial was terminated after enrollment of 861 patients, as mortality was significantly lower in the low-tidal volume ventilation group compared to the high-tidal volume ventilation group (31% *vs* 38.9%, *P* = 0.007)[10].

Although this certainly was a step forward in ARDS treatment, the optimism of this study should be tempered with the following considerations. First, the patient population studied in this trial underrepresents certain patient groups at high risk for ARDS. In particular, trauma patients only accounted for 13% of the patients in the low-tidal volume group and 9% of the patients in the high-tidal volume group[10]. Many trauma patients have well-known risk factors for ARDS development including: Injury Severity scores > 16, thoracic injury or pulmonary contusions with Abbreviated Injury Scale score of > 3, longbone and/or pelvic fractures, and transfusion of > 2 units of blood products within the first 24 h of injury[11]. Second, although the results of the study were statistically significant, in-hospital mortality from ARDS remained quite high at 31%. Lastly, and perhaps most importantly, the overall mortality of ARDS worldwide has not substantially changed since the original ARDSnet study was published and remains static at approximately 40%[12-14].

***ARDS is a progressive disease, and there is a treatment window early in this progression that can be exploited***

Why has ARDS remained a vexing clinical entity, highly resistant to all of our attempts at effective treatment? The answer to this question may lie in the way we view the disease process itself. For decades, ARDS has been viewed through the lens of a binary construct: the disease is either present or it is not. However, this paradigm has started shifting in recent years, and this shift may hold the key to effectively combating ALI and ARDS. In particular, ARDS is now being viewed as a progressive disease with an early treatment window that can be targeted[15-25]. To that end, ARDS investigators are turning their attention toward identifying patients at-risk for developing ALI/ARDS and investigating preventive treatment strategies.

Unfortunately, identifying at-risk patients for ALI has proven difficult. The complexity of this process is highlighted by a recent prospective observational study in three Spanish teaching hospitals. In this study, 815 patients were identified with at least one clinical insult, the most common being sepsis, pneumonia, and pancreatitis[26]. However, the majority of patients in this study with risk factors for developing ALI/ARDS never developed lung injury at all[26]. What is clear across multiple studies, however, is the fact that ALI is rarely present on initial presentation and develops over hours to days while patients are in the hospital[27-30]. Thus, there is a window of opportunity early in the progression of developing lung injury that can be exploited with the following caveat: whatever intervention is used, it must be benign and without deleterious side effects so it can be applied to all patients at high-risk for developing lung injury.

What is clinically needed to make this a reality is a reliable risk factor model that accurately identifies, with a high sensitivity and specificity, those patients who will develop ALI/ARDS. One model that may prove helpful in this regard is the Lung Injury Prediction score (LIPS). The LIPS score is calculated based on a set of predisposing conditions and risk modifiers that are catalogued before the onset of ALI including the presence of shock, sepsis, pneumonia, acute abdomen, smoke inhalation, lung contusion, multiple fractures and acidosis[31]. Benefits of the LIPS score include the use of clinical variables closely associated with lung injury that are easily available on hospital admission and are a usual part of the patient chart[31]. In addition, this model identifies at-risk patients before they are admitted to the intensive care unit (ICU) or suffer a “second hit” that can hasten the progression to ALI[31].

***The only successful treatments thus far are those involving methods of protective mechanical ventilation instituted early in the disease course***

Although a clinical predictive tool like the LIPS score may ultimately prove useful for identifying those patients at risk for developing ALI/ARDS, successfully preventing progression to lung injury has proven equally difficult to solve. To be sure, maximizing supportive care measures and following a standardized bundle of lung injury prevention measures is an important part of this process[15,22]. However, there is no clearly defined treatment to date, either pharmacologic or mechanical, that definitively prevents lung injury.

With this in mind, there is an increasing body of literature demonstrating the beneficial effects of early protective mechanical ventilation on halting the progression toward lung injury. For example, patients undergoing major abdominal, cardiac, or thoracic surgery represent a large patient population at risk for developing ALI[32-34]. The method and technique of mechanical ventilation during surgery, therefore, represent a potential therapeutic intervention for preventing the development of ALI/ARDS in these at-risk surgery patients. One constant across these studies is the following: Protective ventilation strategies in the operating room, using low tidal volume ventilation strategies (6-8 cc/kg), lower the risk of lung injury and pulmonary complications as compared to conventional mechanical ventilation with higher tidal volumes[34]. Employing selective positive end-expiratory pressure (PEEP) levels and using recruitment maneuvers in the operating room may provide further lung protection as well. For example, Futier *et al*[35] (add 35 here as well) demonstrated a 69% decrease in the number of patients requiring ventilatory support within the first seven days after major abdominal surgery. The ventilation strategy used in the operating room was low tidal volume ventilation (tidal volume 6-8 cc/kg) along with a PEEP of 6-8 cm H2O and recruitment maneuvers every 30 min after intubation[35].

It is important to remember that these preemptive strategies of protective mechanical ventilation are not restricted to surgical patients or those patients undergoing major abdominal or thoracic surgery. For those patients with critical illness who are in the ICU setting, protective mechanical ventilation strategies may be of utmost importance as well. Specifically, Determann *et al*[36] compared the effect of conventional tidal volume ventilation (10 cc/kg of predicted body weight) *vs* low tidal volume ventilation (6 cc/kg of predicted body weight) in critically ill patients without ALI at the onset of mechanical ventilation. This trial was stopped prematurely as the development of lung injury was significantly higher in the conventional tidal volume group[36].

**PREEMPTIVE, PROTECTIVE MECHANICAL VENTILATION INSTITUTED BEFORE THE DEVELOPMENT OF CLINICAL MANIFESTATIONS HAS THE POTENTIAL TO REDUCE THE INCIDENCE OF ARDS**

It seems clear, therefore, that mechanical ventilation and the way it is implemented are key factors in determining whether or not patients at-risk for lung injury progress to ALI/ARDS. Thus, if used correctly, mechanical ventilation has the potential to dramatically decrease the incidence of ARDS. This brings up another important question: what method of mechanical ventilation provides the optimal protective breath-to-breath strategy for preventing lung injury?

***Both basic science and clinical studies suggest that APRV is the ideal ventilation strategy for delivering the optimal protective breath***

Work in our laboratory over the past several years has led us to the conclusion that APRV, using a specific MBP, may be the best method of mechanical ventilation for providing the optimal protective breath and ultimately preventing the progression to ALI/ARDS. Our laboratory specializes in a porcine model of secondary ARDS caused by an intestinal ischemia/reperfusion injury and peritoneal sepsis[37]. In 2012 we undertook a study to evaluate the effectiveness of APRV in preventing lung injury in this animal model. Yorkshire pigs were randomized to two mechanical ventilation groups: APRV (10-15 cc/kg tidal volume) and non-preventative ventilation (10 cc/kg tidal volume)[38]. Despite similar markers of systemic inflammation, the APRV group did not develop ARDS and displayed decreased pulmonary inflammation with increased preservation of surfactant proteins[38]. In addition, both the gross and histological appearance of the lungs demonstrated minimal lung injury in the APRV group, while the control group demonstrated significant lung injury and inflammation and progressed to fulminant ARDS (Figure 1)[38].

The significant difference in lung injury between groups prompted us to further evaluate APRV and its effectiveness in preventing lung injury. As the ARDSnet guidelines are the current standard of care for patients with ARDS, we decided to do a comparison study between APRV and the ARDSnet low tidal volume ventilation strategy with our porcine model of ARDS. As with our initial APRV experience, the APRV group in this study did not develop ARDS[39]. In addition, the APRV group demonstrated preservation of lung E-cadherin and surfactant protein A, suggesting APRV can attenuate lung permeability, edema, and surfactant degradation[39]. The ARDSnet ventilation group, on the other hand, developed significant lung injury and ARDS, based on pulmonary parameters along with both the gross and histological appearance of the lungs (Figure 2)[39]. It is important to keep in mind that in this study, low tidal volume protective ventilation was applied after lung injury had developed, similar to current clinical practice. We are currently conducting a study in which low tidal volume ventilation and APRV are both applied preemptively in an attempt to identify the optimally protective breath to block progressive ALI.

The results of these two former studies were clearly dramatic and prompted us to evaluate the mechanical breath profile of APRV to further elucidate its potential for lung protection. To examine the mechanical breath profile of APRV, we used a rat model of lung injury induced by polysorbate lavage[40]. Animals were randomized to one of two groups: A controlled mandatory ventilation group and an APRV group[40]. In the controlled mandatory ventilation group, different levels of PEEP (5, 10, 16, 20, 24 cm H2O) were tested; in the APRV group, the Tlow was set to achieve ratios of the end-expiratory flow rate to peak expiratory flow rate (EEFR to PEFR) of 10%, 25%, 50%, and 75% - the smaller this ratio is, the more time the lung is exposed to low pressure during the release phase[40]. A PEEP of 16 cm H2O in the controlled mandatory ventilation group and an EEFR to PEFR ratio of 75% in the APRV group both minimized alveolar microstrain (*i.e.*, the dynamic change in alveolar size during tidal ventilation) in this study. However, alveolar recruitment was greater in the APRV group with an EEFR to PEFR ratio of 75% (Figure 3)[40].

From a purely clinical perspective, APRV has demonstrated tremendous potential in preventing ALI/ARDS as well. In particular, Dr. Nader Habashi’s clinical work with APRV has demonstrated the benefits of utilizing APRV in trauma patients at risk for developing lung injury. In a systematic review published in 2013, outcomes for patients with early application of APRV at the R Adams Cowley Shock Trauma Centerin Maryland from 2002 to 2005 were compared to patient populations at other trauma centers to evaluate rates of ARDS development and in-hospital mortality[11]. Relevant studies were identified through PubMed and MEDLINE searches from 1995 to 2012 using the keywords trauma and acute respiratory distress syndrome or ARDS and trauma and acute lung injury or ALI[11]. Sixteen studies met the inclusion criteria of being a prospective or retrospective observational studies or cohort studies enrolling 100 or more adult trauma patients with reported ALI/ARDS incidence and in-hospital mortality data[11]. Although the patients at the Shock Trauma Center were in the upper quartile for their injury severity scores, both the incidence of ARDS (1.3%) and the in-hospital mortality (3.9%) were the lowest for this group of patients in whom early APRV was applied (Figure 4)[11]. Although a prospective randomized controlled trial is needed to confirm these results, this systematic review provided convincing evidence that APRV may be precisely the protective mechanical ventilation mode that may be applied prophylactically to all patients as soon as they are intubated to prevent the progression to lung injury or ARDS. In addition, since APRV is a comfortable mode of mechanical ventilation with minimal negative side effects in patients with normal lungs, it can be applied prophylactically to all patients as soon as they are intubated (unpublished observations).

**CONCLUSION**

ARDS remains a troubling clinical entity with an unacceptably high mortality. Treating fulminant ARDS has proven futile for decades; there are currently no effective pharmacologic or mechanical ventilation strategies for curing ARDS, and treatment is relegated to aggressive supportive care measures. Thus, the key to treating this highly morbid disease lies with preventing the disease from ever occurring. Indeed protective mechanical ventilation strategies are being employed in the operating room and in the intensive care unit before the development of lung injury. Moreover, data from both our laboratory and the clinical realm indicate that appropriately setting APRV generates a protective MBP that may be the most viable and accessible method of preventing lung injury and the subsequent progression to ARDS.

**REFERENCES**

1 **Cheung AM**, Tansey CM, Tomlinson G, Diaz-Granados N, Matté A, Barr A, Mehta S, Mazer CD, Guest CB, Stewart TE, Al-Saidi F, Cooper AB, Cook D, Slutsky AS, Herridge MS. Two-year outcomes, health care use, and costs of survivors of acute respiratory distress syndrome. *Am J Respir Crit Care Med* 2006; **174**: 538-544 [PMID: 16763220 DOI: 10.1164/rccm.200505-693OC]

2 **Herridge MS**, Tansey CM, Matté A, Tomlinson G, Diaz-Granados N, Cooper A, Guest CB, Mazer CD, Mehta S, Stewart TE, Kudlow P, Cook D, Slutsky AS, Cheung AM. Functional disability 5 years after acute respiratory distress syndrome. *N Engl J Med* 2011; **364**: 1293-1304 [PMID: 21470008 DOI: 10.1056/NEJMoa1011802]

3 **Rubenfeld GD**, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, Stern EJ, Hudson LD. Incidence and outcomes of acute lung injury. *N Engl J Med* 2005; **353**: 1685-1693 [PMID: 16236739 DOI: 10.1056/NEJMoa050333]

4 **Davidson TA**, Caldwell ES, Curtis JR, Hudson LD, Steinberg KP. Reduced quality of life in survivors of acute respiratory distress syndrome compared with critically ill control patients. *JAMA* 1999; **281**: 354-360 [PMID: 9929089 DOI: 10.1001/jama.281.4.354]

5 **Angus DC**, Musthafa AA, Clermont G, Griffin MF, Linde-Zwirble WT, Dremsizov TT, Pinsky MR. Quality-adjusted survival in the first year after the acute respiratory distress syndrome. *Am J Respir Crit Care Med* 2001; **163**: 1389-1394 [PMID: 11371406 DOI: 10.1164/ajrccm.163.6.2005123]

6 **Weinert CR**, Gross CR, Kangas JR, Bury CL, Marinelli WA. Health-related quality of life after acute lung injury. *Am J Respir Crit Care Med* 1997; **156**: 1120-1128 [PMID: 9351611 DOI: 10.1164/ajrccm.156.4.9611047]

7 **Matthay MA**, Brower RG, Carson S, Douglas IS, Eisner M, Hite D, Holets S, Kallet RH, Liu KD, MacIntyre N, Moss M, Schoenfeld D, Steingrub J, Thompson BT. Randomized, placebo-controlled clinical trial of an aerosolized β₂-agonist for treatment of acute lung injury. *Am J Respir Crit Care Med* 2011; **184**: 561-568 [PMID: 21562125 DOI: 10.1164/rccm.201012-2090OC]

8 **Rice TW**, Wheeler AP, Thompson BT, deBoisblanc BP, Steingrub J, Rock P. Enteral omega-3 fatty acid, gamma-linolenic acid, and antioxidant supplementation in acute lung injury. *JAMA* 2011; **306**: 1574-1581 [PMID: 21976613 DOI: 10.1001/jama.2011.1435]

9 **Spragg RG**, Taut FJ, Lewis JF, Schenk P, Ruppert C, Dean N, Krell K, Karabinis A, Günther A. Recombinant surfactant protein C-based surfactant for patients with severe direct lung injury. *Am J Respir Crit Care Med* 2011; **183**: 1055-1061 [PMID: 21148720 DOI: 10.1164/rccm.201009-1424OC]

10 Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. *N Engl J Med* 2000; **342**: 1301-1308 [PMID: 10793162 DOI: 10.1056/NEJM200005043421801]

11 **Andrews PL**, Shiber JR, Jaruga-Killeen E, Roy S, Sadowitz B, O'Toole RV, Gatto LA, Nieman GF, Scalea T, Habashi NM. Early application of airway pressure release ventilation may reduce mortality in high-risk trauma patients: a systematic review of observational trauma ARDS literature. *J Trauma Acute Care Surg* 2013; **75**: 635-641 [PMID: 24064877 DOI: 10.1097/TA.0b013e31829d3504]

12 **Villar J**, Sulemanji D, Kacmarek RM. The acute respiratory distress syndrome: incidence and mortality, has it changed? *Curr Opin Crit Care* 2014; **20**: 3-9 [PMID: 24309954 DOI: 10.1097/MCC.0000000000000057]

13 **Phua J**, Badia JR, Adhikari NK, Friedrich JO, Fowler RA, Singh JM, Scales DC, Stather DR, Li A, Jones A, Gattas DJ, Hallett D, Tomlinson G, Stewart TE, Ferguson ND. Has mortality from acute respiratory distress syndrome decreased over time?: A systematic review. *Am J Respir Crit Care Med* 2009; **179**: 220-227 [PMID: 19011152 DOI: 10.1164/rccm.200805-722OC]

14 **Villar J**, Blanco J, Añón JM, Santos-Bouza A, Blanch L, Ambrós A, Gandía F, Carriedo D, Mosteiro F, Basaldúa S, Fernández RL, Kacmarek RM. The ALIEN study: incidence and outcome of acute respiratory distress syndrome in the era of lung protective ventilation. *Intensive Care Med* 2011; **37**: 1932-1941 [PMID: 21997128 DOI: 10.1007/s00134-011-2380-4]

15 **Beitler JR**, Schoenfeld DA, Thompson BT. Preventing ARDS: progress, promise, and pitfalls. *Chest* 2014; **146**: 1102-1113 [PMID: 25288000 DOI: 10.1378/chest.14-0555]

16 **Biehl M**, Kashiouris MG, Gajic O. Ventilator-induced lung injury: minimizing its impact in patients with or at risk for ARDS. *Respir Care* 2013; **58**: 927-937 [PMID: 23709192 DOI: 10.4187/respcare.02347]

17 **Festic E**, Kor DJ, Gajic O. Prevention of acute respiratory distress syndrome. *Curr Opin Crit Care* 2015; **21**: 82-90 [PMID: 25501020 DOI: 10.1097/MCC.0000000000000174]

18 **Ortiz-Diaz E**, Festic E, Gajic O, Levitt JE. Emerging pharmacological therapies for prevention and early treatment of acute lung injury. *Semin Respir Crit Care Med* 2013; **34**: 448-458 [PMID: 23934714 DOI: 10.1055/s-0033-1351118]

19 **Hou PC**, Elie-Turenne MC, Mitani A, Barry JM, Kao EY, Cohen JE, Frendl G, Gajic O, Gentile NT. Towards prevention of acute lung injury: frequency and outcomes of emergency department patients at-risk - a multicenter cohort study. *Int J Emerg Med* 2012; **5**: 22 [PMID: 22632126 DOI: 10.1186/1865-1380-5-22]

20 **Litell JM**, Gong MN, Talmor D, Gajic O. Acute lung injury: prevention may be the best medicine. *Respir Care* 2011; **56**: 1546-1554 [PMID: 22008396 DOI: 10.4187/respcare.01361]

21 **Thakur SJ**, Trillo-Alvarez CA, Malinchoc MM, Kashyap R, Thakur L, Ahmed A, Reriani MK, Cartin-Ceba R, Sloan JA, Gajic O. Towards the prevention of acute lung injury: a population based cohort study protocol. *BMC Emerg Med* 2010; **10**: 8 [PMID: 20420711 DOI: 10.1186/1471-227X-10-8]

22 **Levitt JE**, Matthay MA. Clinical review: Early treatment of acute lung injury--paradigm shift toward prevention and treatment prior to respiratory failure. *Crit Care* 2012; **16**: 223 [PMID: 22713281 DOI: 10.1186/cc11144]

23 **Yilmaz M**, Keegan MT, Iscimen R, Afessa B, Buck CF, Hubmayr RD, Gajic O. Toward the prevention of acute lung injury: protocol-guided limitation of large tidal volume ventilation and inappropriate transfusion. *Crit Care Med* 2007; **35**: 1660-166; quiz 1667 [PMID: 17507824]

24 **Shari G**, Kojicic M, Li G, Cartin-Ceba R, Alvarez CT, Kashyap R, Dong Y, Poulose JT, Herasevich V, Garza JA, Gajic O. Timing of the onset of acute respiratory distress syndrome: a population-based study. *Respir Care* 2011; **56**: 576-582 [PMID: 21276315 DOI: 10.4187/respcare.00901]

25 **Fuller BM**, Mohr NM, Hotchkiss RS, Kollef MH. Reducing the burden of acute respiratory distress syndrome: the case for early intervention and the potential role of the emergency department. *Shock* 2014; **41**: 378-387 [PMID: 24469236 DOI: 10.1097/SHK.0000000000000142]

26 **Ferguson ND**, Frutos-Vivar F, Esteban A, Gordo F, Honrubia T, Peñuelas O, Algora A, García G, Bustos A, Rodríguez I. Clinical risk conditions for acute lung injury in the intensive care unit and hospital ward: a prospective observational study. *Crit Care* 2007; **11**: R96 [PMID: 17784960 DOI: 10.1186/cc6113]

27 **Gajic O**, Rana R, Winters JL, Yilmaz M, Mendez JL, Rickman OB, O'Byrne MM, Evenson LK, Malinchoc M, DeGoey SR, Afessa B, Hubmayr RD, Moore SB. Transfusion-related acute lung injury in the critically ill: prospective nested case-control study. *Am J Respir Crit Care Med* 2007; **176**: 886-891 [PMID: 17626910 DOI: 10.1164/rccm.200702-271OC]

28 **Gajic O**, Moore SB. Transfusion-related acute lung injury. *Mayo Clin Proc* 2005; **80**: 766-770 [PMID: 15945528 DOI: 10.4065/80.6.766]

29 **Gajic O**, Dzik WH, Toy P. Fresh frozen plasma and platelet transfusion for nonbleeding patients in the intensive care unit: benefit or harm? *Crit Care Med* 2006; **34**: S170-S173 [PMID: 16617262 DOI: 10.1097/01.CCM.0000214288.88308.26]

30 **Gajic O**, Dara SI, Mendez JL, Adesanya AO, Festic E, Caples SM, Rana R, St Sauver JL, Lymp JF, Afessa B, Hubmayr RD. Ventilator-associated lung injury in patients without acute lung injury at the onset of mechanical ventilation. *Crit Care Med* 2004; **32**: 1817-1824 [PMID: 15343007 DOI: 10.1097/01.CCM.0000133019.52531.30]

31 **Gajic O**, Dabbagh O, Park PK, Adesanya A, Chang SY, Hou P, Anderson H, Hoth JJ, Mikkelsen ME, Gentile NT, Gong MN, Talmor D, Bajwa E, Watkins TR, Festic E, Yilmaz M, Iscimen R, Kaufman DA, Esper AM, Sadikot R, Douglas I, Sevransky J, Malinchoc M. Early identification of patients at risk of acute lung injury: evaluation of lung injury prediction score in a multicenter cohort study. *Am J Respir Crit Care Med* 2011; **183**: 462-470 [PMID: 20802164 DOI: 10.1164/rccm.201004-0549OC]

32 **Futier E**, Godet T, Millot A, Constantin JM, Jaber S. Mechanical ventilation in abdominal surgery. *Ann Fr Anesth Reanim* 2014; **33**: 472-475 [PMID: 25153670 DOI: 10.1016/j.annfar.2014.07.007]

33 **Futier E**, Jaber S. Lung-protective ventilation in abdominal surgery. *Curr Opin Crit Care* 2014; **20**: 426-430 [PMID: 24927044 DOI: 10.1097/MCC.0000000000000121]

34 **Gu WJ**, Wang F, Liu JC. Effect of lung-protective ventilation with lower tidal volumes on clinical outcomes among patients undergoing surgery: a meta-analysis of randomized controlled trials. *CMAJ* 2015; **187**: E101-E109 [PMID: 25512653 DOI: 10.1503/cmaj.141005]

35 **Futier E**, Constantin JM, Paugam-Burtz C, Pascal J, Eurin M, Neuschwander A, Marret E, Beaussier M, Gutton C, Lefrant JY, Allaouchiche B, Verzilli D, Leone M, De Jong A, Bazin JE, Pereira B, Jaber S. A trial of intraoperative low-tidal-volume ventilation in abdominal surgery. *N Engl J Med* 2013; **369**: 428-437 [PMID: 23902482 DOI: 10.1056/NEJMoa1301082]

36 **Determann RM**, Royakkers A, Wolthuis EK, Vlaar AP, Choi G, Paulus F, Hofstra JJ, de Graaff MJ, Korevaar JC, Schultz MJ. Ventilation with lower tidal volumes as compared with conventional tidal volumes for patients without acute lung injury: a preventive randomized controlled trial. *Crit Care* 2010; **14**: R1 [PMID: 20055989 DOI: 10.1186/cc8230]

37 **Kubiak BD**, Albert SP, Gatto LA, Vieau CJ, Roy SK, Snyder KP, Maier KG, Nieman GF. A clinically applicable porcine model of septic and ischemia/reperfusion-induced shock and multiple organ injury. *J Surg Res* 2011; **166**: e59-e69 [PMID: 21193206 DOI: 10.1016/j.jss.2010.10.014]

38 **Roy S**, Sadowitz B, Andrews P, Gatto LA, Marx W, Ge L, Wang G, Lin X, Dean DA, Kuhn M, Ghosh A, Satalin J, Snyder K, Vodovotz Y, Nieman G, Habashi N. Early stabilizing alveolar ventilation prevents acute respiratory distress syndrome: a novel timing-based ventilatory intervention to avert lung injury. *J Trauma Acute Care Surg* 2012; **73**: 391-400 [PMID: 22846945 DOI: 10.1097/TA.0b013e31825c7a82]

39 **Roy S**, Habashi N, Sadowitz B, Andrews P, Ge L, Wang G, Roy P, Ghosh A, Kuhn M, Satalin J, Gatto LA, Lin X, Dean DA, Vodovotz Y, Nieman G. Early airway pressure release ventilation prevents ARDS-a novel preventive approach to lung injury. *Shock* 2013; **39**: 28-38 [PMID: 23247119 DOI: 10.1097/shk.0b013e31827b47bb]

40 **Kollisch-Singule M**, Emr B, Smith B, Roy S, Jain S, Satalin J, Snyder K, Andrews P, Habashi N, Bates J, Marx W, Nieman G, Gatto LA. Mechanical breath profile of airway pressure release ventilation: the effect on alveolar recruitment and microstrain in acute lung injury. *JAMA Surg* 2014; **149**: 1138-1145 [PMID: 25230047 DOI: 10.1001/jamasurg.2014.1829]


**P-Reviewer:** Chen XL, Nseir S **S-Editor:** Ji FF **L-Editor: E-Editor:**

E:\jifangfang\送修稿\2015-08-25\20573\Figure 1.tif


**Figure 1 A gross and histological comparison between airway pressure release ventilation and nonpreventative ventilation.** Left, A and B: Gross pathology of the cut surface of the right lower lobe of the lung of representative animals from (A) the NPV and (B) the APRV group. The NPV shows severe inflammation, bronchial edema, and areas of hemorrhage. The APRV group demonstrates normal, pink, homogenously inflated lungs with little injury on gross appearance; Right, A-D: Histological comparison of four pigs, two NPV (A and C) and two APRV (B and D) at low (A and B) and high (C and D) magnification. The NPV animals show classic stigmata of ARDS including atelectasis, fibrinous exudates, intra-alveolar hemorrhage, congested capillaries, thickened alveolar walls, and leukocytic infiltrates. The APRV animals demonstrate preservation of nearly normal pulmonary architecture. APRV: Airway pressure release ventilation; NPV: Nonpreventative ventilation; ARDS: Acute respiratory distress syndrome.

E:\jifangfang\送修稿\2015-08-25\20573\Figure 2.tif

**Figure 2 Pulmonary, gross and histologic representation between airway pressure release ventilation, LTV and sham animals.** Top: Pulmonary data: A: P/F Ratio: APRV maintains a normal P/F ratio throughout the 48-h study with no significant difference from uninjured sham animals. Low tidal volume ventilation develops ALI (P/F G 300) by 19 h and ARDS (P/F G 250) by 33 h; ventilation strategy does not alter steady progression of increasing hypoxemia (P G 0.001 *vs* APRV and sham);B: Static compliance (Cstat): the APRV shows significant increase in Cstat after transition from volume- cycled mode to APRV (P G 0.001 *vs* sham and LTV ventilation). Sham maintained a normal Cstat level throughout the course of the study. In contrast, the LTV ventilation group developed progressive decreases in Cstat to less than 50% of BL; C: Mean airway pressure: sham group maintained normal Pmean throughout 48-h significantly different from both APRV and LTV ventilation (P G 0.001). Pmean was significantly higher in APRV than in both sham and LTV ventilation after transition from conventional ventilation at 1 h. Because of stepwise increases in PEEP per the ARDSnet protocol, the Pmean was identical from 39 to 48 h for LTV ventilation and APRV; D: Pressure-time profile (P/TP): APRV group had significantly higher P/TP than did both other groups as soon as the transition was made from volume-cycled ventilation (P G 0.001 *vs* sham and LTV ventilation). In the LTV ventilation group, P/TP remained low and did not change over the 48-h course of the study. Sham group animals also had low P/TP, which was not significantly different from the LTV ventilation group throughout the study; Middle: Gross appearance. Representative specimens of gross lungs and cut surface of gross lungs from LTV ventilation (C and D) and APRV (A and B) groups are shown. *Bottom:* Histological appearance. Photomicrographs of representative lung sections of specimens from each treatment group at 40 × magnification are shown. F: Fibrinous deposit in the air compartment; arrow: Blood in alveolus; arrowhead: Congested alveolar capillary; bracket: Thickened alveolar wall. A: Sham: Animals received 48 h of mechanical ventilation and no injury. Specimen exhibits stigmata of lung injury including fibrinous deposits, blood in alveolus, congested capillaries, and thickened alveolar walls; B: Low tidal volume ventilation: animals received aforementioned ischemic injury along with peritoneal sepsis and LTV ventilation after onset of ALI. Specimen exhibits stigmata of lung injury including fibrinous deposits, blood in alveolus, congested capillaries, leukocyte infiltration, and thickened alveolar walls; C: Airway pressure release ventilation: animals received APRV 1 h following aforementioned ischmic injury and peritoneal sepsis. Specimen shows normal pulmonary architecture, alveoli are well expanded and thin walled, and there are no exudates.

****

**Figure 3 *In vivo* photomicrographs and percentage of alveolar air space occupancy at inspiration and expiration.** A: *In vivo* photomicrographs at inspiration and expiration prior to coloring and for positive end-expiratory pressure (PEEP) of 5 cm H2O, airway pressure release ventilation (APRV) ratio of termination of peak expiratory flow rate (T-PEFR) to peak expiratory flow rate (PEFR) of 10%, PEEP of 16 cm H2O, and APRV T-PEFR to PEFR ratio of 75% (original magnification × 10). Alveoli are colored in yellow; nonalveolar tissue, red; B: Alveolar air space occupancy is expressed as a percentage of the photomicrograph containing inflated alveoli (yellow in A) at inspiration and expiration. Data are shown as the mean; error bars indicate standard error of the mean. a*P*< 0.05 for PEEP of 5 cm H2O *vs* APRVT-PEFR to PEFR ratio of 10%; c*P* < 0.05 for PEEP of 16 cm H2O *vs* APRV T-PEFR to PEFR ratio of 75%.



**Figure 4 Boxplots for mean Individual Severity Score (A), acute respiratory distress syndrome % (B), and in-hospital mortality % (C).** Mean ISS shows the range and distribution of ISS scores reported by 16 authors; 50% of them reported ISS between 30.5 and 23.2, with the middle score of 25.4 (median). The mean ISS of 29 for the preemptive APRV group belonged to the upper quartile of the boxplot. ARDS incidence % shows the range and distribution of scores reported by 16 authors; 50% of them reported ARDS incidence between 22.5% and 6%, with the middle score of 11.95% (median). The incidence of ARDS in the preemptive APRV group represented the minimum score at 1.3%. Mortality % shows the range and distribution of mortality scores reported by 16 authors; 50% of them reported mortality between 18.2% and 9.2%, with the middle score of 13.9% (median). The preemptive APRV group scored the minimum mortality rate of 3.9%. ARDS: Acute respiratory distress syndrome; APRV: Airway pressure release ventilation; ISS: Individual Severity Score.